Ana Reis, PhD
-
Antibody-drug conjugatesImmunotoxins: protein toxins as payloads of ADCs
Ana Reis, PhD
When conjugated to antibodies and used in combinatorial therapeutic applications, protein toxins are typically referred to as fusion proteins or immunotoxins. Despite also being classified as payloads of antibody-drug…
-
DNA-damaging agents and transcription inhibitors as payloads of ADCs
DNA-damaging agents are one of the major classes of payloads used in antibody-drug conjugate (ADC) development. Unlike tubulin inhibitors, most… Read More
-
ADC linkers: Definition and examples
ACD linkers can be divided into several classes according to their structure and mechanism of action. Linker chemistry dictates… Read More
-
Linker technology for ADC generation
Experts believe that most challenges tied to the production of ADCs can be overcome by creating better linkers for… Read More
-
A guide to mammalian cell-based expression systems
Mammalian cell-based expression systems are the dominant technology used in the production of biopharmaceuticals. These expression systems excel in terms… Read More
-
A guide to recombinant protein expression: hosts, vectors & tags
Recombinant protein expression is considered one of the most important breakthroughs ever achieved in the life sciences. Decades of research… Read More
-
Tubulin inhibitors as payloads of ADCs
Payloads are the pharmaceutical component of antibody-drug conjugates (ADCs). Often these components are small drugs too toxic to be administered… Read More
-
ADC payloads
Antibody-drug conjugates (ADCs) are an emerging class of pharmaceuticals designed to deliver highly toxic cargoes (payloads) to clinical targets. Read More
-
The structure of CAR-T cells
CAR-T cell therapy is an emerging alternative to conventional anticancer treatments. Over the years, these modified cells have demonstrated promising… Read More
-
CAR-T cell immunotherapy
CAR-T cells are a form of adoptive T cell therapy (ACT). This emerging technology combines the cytotoxic potential of T… Read More
